Cited by 3,011Hepatitis C virus researchLiver Disease Diagnosis and TreatmentLiver physiology and pathology

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Poynard, Thierry, Bedossa, Pierre, Opolon, Pierre·1997·The Lancet

Open this paper in CoChat — free account

Abstract

Background Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression. Methods We recruited 2235 patients from the Observatoire de l'Hépatite C (OBSVIRC) population, the Cohorte Hépatite C Pitié-Salpétrière (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, F0 = no fibrosis, F4 = cirrhosis, and histological activity on a four-point scale, A0 = no activity, A3 = severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained. We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit = one stage, 4 units = cirrhosis). Findings The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years. Interpretation The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(96)07642-8

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bédossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,107
Self-citation
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M. A., Hoofnagle, J. H., Manns, M. P., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,591
Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C
Bédossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,212
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,191
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
Poynard, T., Leroy, V., Cohard, M., Thévenot, T., Mathurin, P., Opolon, P., & Zarski, J. (1996) · Hepatology · doi:10.1002/hep.510240405 · Cited by 671
Self-citation
The Long–Term Pathological Evolution of Chronic Hepatitis C
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., INOUE, O., Hashimoto, E., Lefkowitch, J. H., Ludwig, J., & Okuda, K. (1996) · Hepatology · doi:10.1002/hep.510230607 · Cited by 597
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
Bisceglie, A. M. D., Goodman, Z. D., Ishak, K. G., Hoofnagle, J. H., Melpolder, J. J., & Alter, H. J. (1991) · Hepatology · doi:10.1002/hep.1840140603 · Cited by 538
Epidemiology of Hepatitis C in the West
Alter, M. J. (1995) · Seminars in Liver Disease · doi:10.1055/s-2007-1007259 · Cited by 482
A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis
Poynard, T., Bédossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., TREPO, C. G., Couzigou, P., Payen, J. L., Sajus, M., Costa, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322201 · Cited by 454
Self-citation

Show all 24 references

Research works printed but not linked: 1

1995, Bilan initial. Association Francoise pour ľEtude du Foie, Lyon 1994, Gastroenterol Clin Biol, 19, 81

Sorted by citations

Items 701–800 of 1,001

Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology
Schmidt, W. N., Stapleton, J. T., LaBrecque, D. R., Mitros, F. A., Kirby, P., Phillips, M. J. P., & Brashear, D. L. (2000) · Hepatology · doi:10.1002/hep.510310326 · Cited by 59
In vitro chronic hepatic disease characterization with a multiparametric ultrasonic approach
Meziri, M., Pereira, W. C. D. A., Abdelwahab, A., Degott, C., & Laugier, P. (2004) · Ultrasonics · doi:10.1016/j.ultras.2004.09.002 · Cited by 59
Chronic Hepatitis C and Interferon Alpha: Conventional and Cumulative Meta-Analyses of Randomized Controlled Trials
Cammà, C., Giunta, M., Pinzello, G., Morabito, A., Verderio, P., & Pagliaro, L. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00800-4 · Cited by 59
Alcoholic Liver Disease
Joshi, K., Kohli, A., Manch, R., & Gish, R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.02.012 · Cited by 58
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care
Innes, H. A., Hutchinson, S. J., Allen, S. H., Bhattacharyya, D., Bramley, P. N., Delahooke, T., Dillon, J. F., Forrest, E. H., Fraser, A. G., Gillespie, R. J., et al. (2011) · Hepatology · doi:10.1002/hep.24561 · Cited by 58
Redox regulation of hepatitis C in nonalcoholic and alcoholic liver
Seronello, S., Sheikh, M. Y., & Choi, J. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.036 · Cited by 58
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation
Manousou, P., Burroughs, A. K., Tsochatzis, E. A., Isgrò, G., Hall, A. R., Green, A., Calvaruso, V., Li, G., Gale, J. D., Burgess, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.016 · Cited by 58
Liver fibrosis staging with diffusion-weighted imaging: a systematic review and meta-analysis
Jiang, H., Chen, J., Gao, R., Huang, Z., Wu, M., & Song, B. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-0913-6 · Cited by 58
Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies
Fassio, E., Álvarez, E., Domínguez, N., Landeira, G., & Longo, C. (2004) · Hepatology · doi:10.1002/hep.1840400411 · Cited by 58
Irregular Regeneration of Hepatocytes Is An Important Factor in the Hepatocarcinogenesis of Liver Disease
Ueno, Y., Moriyama, M., Uchida, T., & Arakawa, Y. (2001) · Hepatology · doi:10.1053/jhep.2001.21902 · Cited by 58
Comparing the public health burden of chronic hepatitis C and HIV infection in France
Deuffic‐Burban, S., Wong, J. B., Valleron, A., Costagliola, D. G., Delfraissy, J., & Poynard, T. (2003) · Journal of Hepatology · doi:10.1016/j.jhep.2003.10.018 · Cited by 58
Self-citation
Effects of psycho-educational intervention on health-related quality of life (QOL) of patients with chronic liver disease referring to Shiraz University of Medical Sciences
Sharif, F., Mohebbi, S., Tabatabaee, H., Saberifiroozi, M., & Gholamzadeh, S. (2005) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-3-81 · Cited by 58
Steatosis and fibrosis in patients with chronic hepatitis C
Wyatt, J. I., Baker, H., Prasad, P., Gong, Y. Y., & Millson, C. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.009357 · Cited by 58
Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy
Tabone, M., Sidoli, L., Laudi, C., Pellegrino, S., Rocca, G., Monica, P. D., Fracchia, M., GALATOLA, G., Molinaro, G., Aricò, S., et al. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00360.x · Cited by 58
Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center
Forns, X., Ampurdanés, S., Sánchez‐Tapias, J. M., Guilera, M., Sans, M., Fueyo, A. S., Quintó, L., Joya, P., Bruguera, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00088-5 · Cited by 57
Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development
Nakamoto, S., Imazeki, F., Fukai, K., Fujiwara, K., Arai, M., Kanda, T., Yonemitsu, Y., & Yokosuka, O. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.001 · Cited by 57
Turnover Rates of Hepatic Collagen and Circulating Collagen-Associated Proteins in Humans with Chronic Liver Disease
Decaris, M. L., Emson, C. L., Li, K. W., Gatmaitan, M., Luo, F., Cattin‐Ortolá, J., Nakamura, C., Holmes, W. E., Angel, T. E., Peters, M. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123311 · Cited by 57
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease
Trépo, E., Potthoff, A., Pradat, P., Bakshi, R. K., Young, B. A., LAGIER, R. J., Moreno, C., Verset, L., Cross, R., Degré, D., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.018 · Cited by 57
Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008–2013: A nationwide retrospective cohort study
Schwarzinger, M., Baillot, S., Yazdanpanah, Y., Rehm, J. T., & Mallet, V. O. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.031 · Cited by 57
Natural history of chronic hepatitis B and C
Imperial, J. C. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01903.x · Cited by 57
Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C
Geier, A., Reugels, M. J., Weiskirchen, R., Wasmuth, H. E., Dietrich, C. G., Siewert, E., Gartung, C., Lorenzen, J., Bosserhoff, A., Brügmann, M., et al. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0928.x · Cited by 57
Multi‐state Markov models for disease progression in the presence of informative examination times: An application to hepatitis C
Sweeting, M. J., Farewell, V. T., & Angelis, D. D. (2010) · Statistics in Medicine · doi:10.1002/sim.3812 · Cited by 57
Gender Differences Among Patients Hospitalized With Cirrhosis in the United States
Rubin, J. B., Sundaram, V., & Lai, J. C. (2019) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001192 · Cited by 56
Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?
Harris, H., Eldridge, K. P., Harbour, S., Alexander, G., Teo, C., Ramsay, M. E., & The HCV National Register Steering Group (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00795.x · Cited by 56
Polymorphism of the TLR4 Gene Reduces the Risk of Hepatitis C Virus-Induced Hepatocellular Carcinoma
Agúndez, J. A. G., García‐Martín, E., Devesa, M. J., Carballo, M., Martı́nez, C., Lee-Brunner, A., Fernández, C., Díaz‐Rubio, M., & Ladero, J. M. (2012) · Oncology · doi:10.1159/000335606 · Cited by 56
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection†‡
Fontana, R. J., Kleiner, D. E., Bilonick, R. A., Terrault, N. A., Afdhal, N. H., Belle, S. H., Jeffers, L. J., Ramcharran, D., Ghany, M. G., & Hoofnagle, J. H. (2006) · Hepatology · doi:10.1002/hep.21335 · Cited by 56
Risk Factors for Infection During Treatment with Peginterferon alfa and Ribavirin for Chronic Hepatitis C
Roomer, R., Hansen, B. E., Janssen, H. L. A., & de Knegt, R. J. (2010) · Hepatology · doi:10.1002/hep.23842 · Cited by 56
Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected
Eyawo, O., McGinnis, K. A., Justice, A. C., Fiellin, D. A., Hahn, J. A., Williams, E. C., Gordon, A. J., Marshall, B. D. L., Kraemer, K. L., Crystal, S., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001588 · Cited by 55
Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)
Wagner, R., Randolph, J. T., Patel, S. V., Nelson, L. T. J., Matulenko, M. A., Keddy, R. G., Pratt, J. K., Liu, D., Krueger, A. C., Donner, P. L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00082 · Cited by 56
Alcoholic Liver Disease in the Elderly
Seitz, H. K., & Stickel, F. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2007.06.010 · Cited by 56
THE NATURAL HISTORY OF CHRONIC HEPATITIS C VIRUS INFECTION
Seeff, L. B. (1997) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70323-8 · Cited by 55
The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection
Berger, A., Preiser, W., & Doerr, H. W. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00151-7 · Cited by 56
CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection
Hoare, M., Gelson, W. T. H., Das, A., Fletcher, J. M., Davies, S. E., Curran, M. D., Vowler, S. L., Maini, M. K., Akbar, A. N., & Alexander, G. J. M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.005 · Cited by 53
Cardiovascular Implications of Immune Disorders in Women
Moran, C. A., Collins, L. F., Beydoun, N., Mehta, P. K., Fatade, Y., Isiadinso, I., Lewis, T. T., Weber, B., Goldstein, J. M., Ofotokun, I., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319877 · Cited by 57
The Burden of Hepatitis C Virus Infection Is Growing: A Canadian Population-Based Study of Hospitalizations from 1994 to 2004
Myers, R. P., Liu, M., & Shaheen, A. A. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/173153 · Cited by 55
Alcohol and Hepatitis C Mortality Among Males and Females in the United States: A Life Table Analysis
Chen, C. M., Yoon, Y., Yi, H., & Lucas, D. L. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00304.x · Cited by 55
Drug Interactions Between Psychoactive Substances and Antiretroviral Therapy in Individuals Infected With Human Immunodeficiency and Hepatitis Viruses
Neuman, M. G., Monteiro, M. G., & Rehm, J. T. (2006) · Substance Use & Misuse · doi:10.1080/10826080600846235 · Cited by 54
Hepatitis C Infection and Hepatocellular Carcinoma After Treatment of Childhood Cancer
Strickland, D. K., Jenkins, J. J., & Hudson, M. M. (2001) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200111000-00012 · Cited by 55
Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C
Macı́as, J., Mira, J. A. L., López-Cortés, L. F., Santos, I. D. L., González, J. A. G., González‐Serrano, M., Merino, D., Hernández‐Quero, J., Rivero, A., Merchante, N., et al. (2006) · Antiviral Therapy · doi:10.1177/135965350601100701 · Cited by 55
Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients
Elemeery, M. N., Badr, A. N., Mohamed, M. A., & Ghareeb, D. A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i21.3864 · Cited by 54
Managing chronic hepatitis C acquired through intravenous drug use
Jowett, S. L. (2001) · QJM · doi:10.1093/qjmed/94.3.153 · Cited by 55
A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: Is it safe and useful?
Shin, J. L., Teitel, J. M., Swain, M. G., Bain, V. G., Adams, P. C., Croitoru, K., Peltekian, K. M., Schweiger, F., Simons, M. E., & Heathcote, E. J. (2005) · American Journal of Hematology · doi:10.1002/ajh.20263 · Cited by 55
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
Wong, J. B., Davis, G. L., McHutchison, J. G., Manns, M. P., & Albrecht, J. K. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.08.027 · Cited by 55
Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3
Barreiro, P., Martín‐Carbonero, L., Nunez, M., Rivas, P., Morente, A., Simarro, N., Labarga, P., González‐Lahoz, J., & Soriano, V. (2006) · Clinical Infectious Diseases · doi:10.1086/501021 · Cited by 55
A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C
Richardson, M. M., Powell, E. E., Barrie, H. D., Clouston, A. D., Purdie, D., & Jonsson, J. R. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.032557 · Cited by 55
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy
Moucari, R., Ripault, M., Oulès, V., Martinot-Peignoux, M., Asselah, T., Boyer, N., Ray, A. A. E., Cazals-Hatem, D. L., Vidaud, D., Valla, D. C., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.10.016 · Cited by 55
Treatment of Alcoholic Hepatitis
O’Shea, R. S., & McCullough, A. J. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.11.004 · Cited by 55
The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C
McKiernan, S. M., Hagan, R., Curry, M. P., McDonald, G. S. A., Nolan, N. P., Crowley, J., Hegarty, J. E., Lawlor, E., & Kelleher, D. P. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70365-9 · Cited by 56
The virtuosity of hepatic stellate cells
Friedman, S. L. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70413-0 · Cited by 54
Modelling the hepatitis C virus epidemic in Australia
Law, M. G. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.02014.x · Cited by 55
Ribavirin plus interferon versus interferon for chronic hepatitis C
Brok, J. S., Gluud, L. L., & Gluud, C. N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005445 · Cited by 55
Burden of Cirrhosis and Other Chronic Liver Diseases Caused by Specific Etiologies in China, 1990-2016: Findings from the Global Burden of Disease Study 2016.
Li, M., Wang, Z. Q., Zhang, L., Zheng, H., Liu, D. W., & Zhou, M. G. (2020) · PubMed · doi:10.3967/bes2020.001 · Cited by 53
Is interleukin-10 gene polymorphism a predictive marker in HCV infection?
Świątek, B. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.01.005 · Cited by 54
Mutations in the NS5A and E2‐PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin
Hung, C., Lee, C. ‐., Lu, S., Lee, J. ‐., Wang, J. ‐., Tung, H., Chen, T. ‐., Hu, T., Chen, W., & Changchien, C. ‐. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00414.x · Cited by 54
Noninvasive classification of hepatic fibrosis based on texture parameters from double contrast‐enhanced magnetic resonance images
Bahl, G., Cruite, I., Wolfson, T. J., Gamst, A. C., Collins, J. M., Chavez, A. D., Barakat, F., Hassanein, T., & Sirlin, C. B. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23759 · Cited by 54
Sex Differences in Rat Intervertebral Disc Structure and Function Following Annular Puncture Injury
Mosley, G. E., Hoy, R. C., Nasser, P. R., Kaseta, T., Lai, A., Evashwick‐Rogler, T. W., Lee, M., & Iatridis, J. C. (2019) · Spine · doi:10.1097/brs.0000000000003055 · Cited by 55
Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C
Takeda, T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i48.7768 · Cited by 54
Hepatitis C and alcohol.
Schiff, E. R., & Ozden, N. (2003) · Europe PMC (PubMed Central) · Cited by 54
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia
Bjøro, K. (1999) · QJM · doi:10.1093/qjmed/92.8.433 · Cited by 54
Hla Class Ii Genes Determine the Natural Variance of Hepatitis C Viral Load
Fanning, L. J., Levis, J., Kenny-Walsh, E., Whelton, M. J., O’Sullivan, K., & Shanahan, F. (2001) · Hepatology · doi:10.1053/jhep.2001.20642 · Cited by 53
10 Worldwide prevalence and prevention of hepatitis c
Lavanchy, D., & McMahon, B. J. (2000) · Biomedical research reports · doi:10.1016/s1874-5326(00)80014-9 · Cited by 54
The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity
Fu, K., Wang, C., Ma, C., Zhou, H., & Li, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771459 · Cited by 53
Gender-based disparities in access to and outcomes of liver transplantation
Oloruntoba, O. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.460 · Cited by 55
PNPLA3 I148M (rs738409) genetic variant and age at onset of at‐risk alcohol consumption are independent risk factors for alcoholic cirrhosis
Burza, M. A., Molinaro, A., Attilia, M. L., Rotondo, C., Attilia, F., Ceccanti, M., Ferri, F., Maldarelli, F., Maffongelli, A., Santis, A. D., et al. (2013) · Liver International · doi:10.1111/liv.12310 · Cited by 53
The lived experience of men and women with hepatitis C: implications for support needs and health information
Temple-Smith, M. J., Gifford, S. M., & StoovÚ, M. (2004) · Australian Health Review · doi:10.1071/ah042720046 · Cited by 53
Stem and progenitor cells in liver regeneration and repair
Russo, F. P., & Parola, M. (2011) · Cytotherapy · doi:10.3109/14653249.2010.545386 · Cited by 53
Adverse outcome pathway development from protein alkylation to liver fibrosis
Horvat, T., Landesmann, B., Lostia, A., Vinken, M., Munn, S., & Whelan, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1814-8 · Cited by 56
Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling.
Delire, B., Lebrun, V., Selvais, C., Henriet, P., Bertrand, A., Horsmans, Y., & Leclercq, I. A. (2016) · Aging · doi:10.18632/aging.101124 · Cited by 49
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐ and post‐universal access to direct‐acting antiviral treatment in Australia: The LiveRLife study
Bajis, S., Grebely, J., Hajarizadeh, B., Applegate, T. L., Marshall, A. D., Harrod, M. E., Byrne, J., Bath, N., Read, P. J., Edwards, M., et al. (2019) · Journal of Viral Hepatitis · doi:10.1111/jvh.13233 · Cited by 53
The natural history of hepatitis C with severe hepatic fibrosis
Lawson, A., Hagan, S., Rye, K., Taguri, N., Ratib, S., Zaitoun, A. M., Neal, K. R., Ryder, S. D., & Irving, W. L. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.010 · Cited by 53
Hepatitis C and Alcohol
Regev, A., & Jeffers, L. J. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04679.x · Cited by 53
Liver Transplantation in Alcoholic Patients
Testino, G., Leone, S., Sumberaz, A., & Borro, P. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12242 · Cited by 53
Epidemiology of Hepatocellular Carcinoma
El‐Serag, H. B. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch59 · Cited by 53
Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C
Lebray, P., Zylberberg, H., Hüe, S., Poulet, B., Carnot, F., Martin, S., Chrétien, Y., Pol, S., Caillat‐Zucman, S., Bréchot, C., et al. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00488.x · Cited by 52
Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients
Stoop, J. N., Claassen, M. A. A., Woltman, A. M., Binda, R. S., Kuipers, E. J., Janssen, H. L. A., Molen, R. G. V. D., & Boonstra, A. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.029 · Cited by 52
Community‐based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use
Wilkinson, M., CRAWFORD, V., Tippett, A., Jolly, F., Turton, J. R. H., SIMS, E., Hekker, M. D., DALTON, J., Marley, R., & Foster, G. R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03834.x · Cited by 52
Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection
Sypsa, V., Touloumi, G., Tassopoulos, N., Ketikoglou, I., Vafiadis, I., Hatzis, G., Tsantoulas, D., Akriviadis, E., Delladetsima, J., Demonakou, M., et al. (2004) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2004.00517.x · Cited by 57
Liver resection in obese patients: results of a case–control study
Viganò, L., Kluger, M. D., Laurent, A., Tayar, C., Merle, J., Lauzet, J.-Y., Andréoletti, M., & Cherqui, D. (2010) · HPB · doi:10.1111/j.1477-2574.2010.00252.x · Cited by 52
Hepatitis C: epidemiology and review of complementary/alternative medicine treatments.
Patrick, L. (1999) · PubMed · Cited by 52
Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C
Hsieh, M., Dai, C., Lee, L., Huang, J.-F., Tsai, W.-C., Hou, N.-J., Lin, Z.-Y., Chen, S.-C., Wang, L.-Y., Wy, C., et al. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.046276 · Cited by 52
A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C
ATTALLAH, A., Shiha, G. E.-S., Omran, M. M., & Zalata, K. R. (2006) · Hepatology Research · doi:10.1016/j.hepres.2005.12.004 · Cited by 51
Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
Roomer, R., Hansen, B. E., Janssen, H. L. A., & de Knegt, R. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.013 · Cited by 51
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis
van der Meer, A. J., Maan, R., Veldt, B. J., Feld, J. J., Wedemeyer, H. H., Dufour, J., Lammert, F., Duarte‐Rojo, A., Manns, M. P., Zeuzem, S., et al. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13252 · Cited by 51
Association Between Helicobacter pylori Infection and Cirrhosis in Patients with Chronic Hepatitis C Virus
Queiroz, D. M. M., Rocha, A. M. C., Rocha, G. A., Cinque, S., de Oliveira, A. G., Godoy, A., & Tanno, H. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-3150-y · Cited by 51
Hepatitis C and alcohol.
Regev, A., & Jeffers, L. J. (1999) · PubMed · Cited by 51
Quantification of Viral Load: Clinical Relevance for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus Infection
Berger, A., Braner, J., Doerr, H. W., & Weber, B. (1998) · Intervirology · doi:10.1159/000024912 · Cited by 51
Differences in hepatocellular iron metabolism underlie sexual dimorphism in hepatocyte ferroptosis
Tao, H., Dar, H. Y., Tian, C. L., Banerjee, S., Glazer, E. S., Srinivasan, S., Zhu, L., Pacifici, R., & He, P. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102892 · Cited by 50
IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection
Chen, J.-Y., Lin, C.-Y., Wang, C. M., Lin, Y.-T., Kuo, S.-N., Shiu, C.-F., Chang, S.-W., Wu, J., & Sheen, I.-S. (2011) · Genes and Immunity · doi:10.1038/gene.2011.1 · Cited by 50
Role of cytokine gene polymorphism and hepatic transforming growth factor β1 expression in recurrent hepatitis C after liver transplantation
Ben‐Ari, Z., Pappo, O., Druzd, T., Sulkes, J., Klein, T., Samra, Z., Gadba, R., Tambur, A. R., Tur‐Kaspa, R., & Mor, E. (2004) · Cytokine · doi:10.1016/j.cyto.2004.03.009 · Cited by 50
Cirrhosis of Mixed Etiology (Hepatitis C Virus and Alcohol): Posttransplantation Outcome—Comparison with Hepatitis C Virus–Related Cirrhosis and Alcoholic-Related Cirrhosis
Aguilera, V., Berenguer, M., Rubín, Á., Sanjuán, F., Rayón, J.-M., Prieto, M., & Mir, J. (2008) · Liver Transplantation · doi:10.1002/lt.21626 · Cited by 50
Hepatitis C virus core protein induces fibrogenic actions of hepatic stellate cells via toll-like receptor 2
Coenen, M., Nischalke, H. D., Krämer, B., Langhans, B., Glässner, A., Schulte, D., Körner, C., Sauerbruch, T., Nattermann, J., & Spengler, U. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.78 · Cited by 51
Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study
Bruggmann, P., Dampz, M., Gerlach, T., Kravecz, L., & Falcato, L. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.02.016 · Cited by 50
Hepatitis C Virus (HCV)–Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection
Thurairajah, P. H., Hegazy, D., Chokshi, S., Shaw, S. R., Demaine, A. G., Kaminski, E. R., Naoumov, N. V., & Cramp, M. (2008) · The Journal of Infectious Diseases · doi:10.1086/593337 · Cited by 54
Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update
Erman, A., Krahn, M. D., Hansen, T., Wong, J., Bielecki, J. M., Feld, J. J., Wong, W. W. L., Grootendorst, P., & Thein, H.-H. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027491 · Cited by 50
Hepatic Inflammation May Influence Liver Stiffness Measurements by Transient Elastography in Children and Young Adults
Raizner, A., Shillingford, N., Mitchell, P. D., Harney, S., Raza, R., Serino‐Cipoletta, J., Jonas, M. M., & Lee, C. K. (2016) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001376 · Cited by 50
Liver transplantation in alcoholic patients
Burra, P., & Lucey, M. R. (2005) · Transplant International · doi:10.1111/j.1432-2277.2005.00079.x · Cited by 50
Barriers to Treatment of Hepatitis C in HIV/HCV‐Coinfected Adults with Alcohol Problems
Nunes, D., Saitz, R., Libman, H., Cheng, D. M., Vidaver, J., & Samet, J. H. (2006) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00183.x · Cited by 50
Liver tissue examination
Desmet, V. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00138-7 · Cited by 50
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update
Poynard, T., Muntenau, M., Morra, R., Ngo, Y., Imbert‐Bismut, F., Thabut, D., Messous, D., Massard, J., Lebray, P., Moussalli, J., et al. (2008) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(08)73990-3 · Cited by 50
Self-citation
Evaluation of fibrosis and hepatitis C
Friedman, S. L. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00377-0 · Cited by 50

Authors: Poynard, T., Bedossa, P., & Opolon, P.
Affiliations: Centre National de la Recherche Scientifique (FR)
Corresponding author: Poynard, Thierry
ORCID: Poynard, Thierry
Venue: The Lancet
Publisher: Elsevier BV
Published: 1997-03
Volume: 349
Issue: 9055
Pages: 825-832
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(96)07642-8
OpenAlex: W2132290252
Cited by: 3,011
References: 24
Citations by year: 2026: 16 · 2025: 35 · 2024: 33 · 2023: 38 · 2022: 43 · 2021: 45 · 2020: 71 · 2019: 74 · 2018: 72 · 2017: 90 · 2016: 117 · 2015: 141 · 2014: 120 · 2013: 138 · 2012: 114
FWCI: 60.07
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: Association pour la Recherche sur le Cancer
Assistance Publique - Hôpitaux de Paris
Assistance publique-Hôpitaux de Paris
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: chronic hepatitis C, liver fibrosis progression, natural history (disease), METAVIR scoring, liver cirrhosis, age at infection, alcohol consumption, sex differences, HCV genotypes, HCV viraemia, host factors, infection duration, histological activity, liver biopsy
MeSH terms: Adult, Age Factors, Alcohol Drinking, Biopsy, Cross-Sectional Studies, Female, Hepatitis, Chronic, Hepatitis C, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Risk Factors, Sex Factors, Time Factors, Prevalence, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks